Exploring the connection between hidradenitis suppurativa and erythema nodosum: a case report
https://doi.org/10.4081/dr.2024.9866
Accepted: 3 December 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: Erythema nodosum (EN) is inflammation of subcutaneous fat. Etiologies include autoimmune diseases, drugs, infections, pregnancy, malignancy, and idiopathic origins. Case: A 37- year-old female with a history of recurrent cellulitis and type II diabetes presented with worsening swollen lumps on upper extremities for four months during a Hurley Stage III hidradenitis suppurativa (HS) flare. Exam revealed multiple erythematous pustules and warm indurated nodules over diffuse edema on the upper extremities. Lesions were refractory to trimethoprim/sulfamethoxazole, cefalexin, clindamycin and levofloxacin. Routine blood labs, ESR, and ANA were unremarkable. EN was diagnosed. Trimethoprim/sulfamethoxazole, saturated solution potassium iodide (SSKI) and ibuprofen were prescribed. At three week follow-up, EN had completely resolved except for one lesion. Discussion: Literature review revealed one case of EN manifestation in association with HS but was complicated by Beçhet’s syndrome. We propose HS as an underlying cause of EN and SSKI an effective treatment for EN and HS.
Leung, A.K.C., K.F. Leong, and J.M. Lam, Erythema nodosum. World J Pediatr, 2018. 14(6): p. 548-554. DOI: https://doi.org/10.1007/s12519-018-0191-1
Perez-Garza, D.M., et al., Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol, 2021. 22(3): p. 367-378. DOI: https://doi.org/10.1007/s40257-021-00592-w
Schwartz, R.A. and S.J. Nervi, Erythema nodosum: a sign of systemic disease. Am Fam Physician, 2007. 75(5): p. 695-700.
Scheinfeld, N., Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J, 2013. 19(6): p. 18558. DOI: https://doi.org/10.5070/D3196018558
Kurzen, H., et al., What causes hidradenitis suppurativa? Exp Dermatol, 2008. 17(5): p. 455-6; discussion 457-72. DOI: https://doi.org/10.1111/j.1600-0625.2008.00712.x
Cartron, A. and M.S. Driscoll, Comorbidities of hidradenitis suppurativa: A review of the literature. Int J Womens Dermatol, 2019. 5(5): p. 330-334. DOI: https://doi.org/10.1016/j.ijwd.2019.06.026
Shalom, G., et al., Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol, 2015. 173(2): p. 464-70. DOI: https://doi.org/10.1111/bjd.13777
Fimmel, S. and C.C. Zouboulis, Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol, 2010. 2(1): p. 9-16. DOI: https://doi.org/10.4161/derm.2.1.12490
Scala, E., et al., Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 2021. 10(8). DOI: https://doi.org/10.3390/cells10082094
Guet-Revillet, H., et al., Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis, 2014. 20(12): p. 1990-8. DOI: https://doi.org/10.3201/eid2012.140064
Hayashi, S., et al., Anti-Inflammatory Effects of Potassium Iodide on SDS-Induced Murine Skin Inflammation. J Invest Dermatol, 2020. 140(10): p. 2001-2008. DOI: https://doi.org/10.1016/j.jid.2020.01.028
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
